LG 4

Introduction

  • Speaker: Dr. Sherwan Nankali, Assoc. Prof. at Hawler Medical University
  • Topic: Physiology of Erection and Ejaculation
  • Year: 2025-2026

Case Studies Introduction

  • Three clinical cases related to erectile and ejaculation dysfunction to illustrate the physiological mechanisms involved.

Case Study 1

Patient Profile

  • Age: 50 years old
  • Symptoms: Difficulty in achieving and maintaining an erection for 6 months.
  • History: No psychological stress; has hypertension and is on beta-blocker therapy.
  • Lifestyle Changes: None reported; denies trauma.
  • Sexual Desire: Experienced but fails to achieve rigidity during intercourse.

Discussion Questions

  1. Primary Physiological Mechanism Impaired: What is primarily impaired in this patient’s condition?
  2. Medication Impact: How does his medication (beta-blocker) contribute to these symptoms?
  3. Pharmacological Treatment: What treatment options can be offered to improve his condition?

Hypertension and Erectile Dysfunction

  • Mechanisms:
    • Hypertension can impair both blood vessels and nerves.
    • Causes endothelial dysfunction leading to reduced blood flow, which is essential for penile artery dilation.
Beta-Blockers and Erectile Dysfunction
  • Mechanism:
    • Reduce sympathetic nervous system activity affecting sexual arousal and penile smooth muscle relaxation.
    • Decrease in cardiac output and blood pressure results in reduced perfusion to the penis.
  • Types of Beta-Blockers:
    • Non-vasodilatory beta-blockers (e.g., atenolol, metoprolol) more likely to cause erectile dysfunction.
    • Vasodilatory beta-blockers (e.g., nebivolol) can release nitric oxide and may have lesser erectile dysfunction side effects.

First-Line Treatment

  • Phosphodiesterase Type 5 (PDE5) Inhibitors:
    • Example medications: sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra).
    • Mechanism of Action:
    • Enhance nitric oxide signaling.
    • Promote smooth muscle relaxation and increase blood flow to the penis.
  • Alternative Options:
    • Switching to a vasodilatory beta-blocker may improve erectile function.
    • Other antihypertensives: ACE inhibitors, ARBs, calcium channel blockers to lower erectile dysfunction risk.

Case Study 2

Patient Profile

  • Age: 35 years old
  • Symptoms: Complains of premature ejaculation, occurring often within a minute of penetration.
  • History: No genitourinary issues previously; this problem affects relationship.

Discussion Questions

  1. Phase Affected: Which phase of ejaculation is likely affected in this patient?
  2. Neural Pathways: What are the neural pathways involved?
  3. Therapeutic Approaches: What treatment options can be considered?

Premature Ejaculation

  • Symptoms: Suggestive of premature ejaculation.
  • Affected Phase: Expulsion phase; involves rhythmic contractions of pelvic floor muscles to propel semen.
  • Neural Control:
    • Controlled by somatic nervous system via the pudendal nerve, impacting bulbospongiosus and ischiocavernosus muscles.
    • Spinal reflexes at S2-S4 coordinate contractions.

Treatment Options

Behavioral Techniques:

  • “Start-stop” and “squeeze” methods to improve ejaculate control.

Pharmacological Options:

  • Selective Serotonin Reuptake Inhibitors (SSRIs):
    • Examples: paroxetine, dapoxetine; delay ejaculation by modulating serotonin levels.
  • Topical Anesthetics:
    • Creams or sprays (e.g., lidocaine, prilocaine) to reduce sensitivity and prolong the duration before ejaculation occurs.

Case Study 3

Patient Profile

  • Age: 40 years old
  • History: Spinal cord injury at T10 level; inability to achieve an erection even with tactile stimulation.
  • Psychological Issues: Denies any; reflexes below injury are diminished.

Discussion Questions

  1. Type of Erection Impaired: Which type (psychogenic or reflexogenic) is impaired and why?
  2. Critical Spinal Level: Which spinal level is crucial for reflexogenic erection?
  3. Pharmacological Treatment Response: Is this condition likely to respond to treatment?

Erection Mechanism & Impairments

  • Reflexogenic Erection: Triggered by tactile stimulation, relies on sacral spinal segments (S2-S4).
    • Often preserved in higher spinal cord injuries.
  • Psychogenic Erection: Initiated by mental/emotional stimuli; dependent on signals traveling through T11-L2.
  • Implication in Current Case: Reflexogenic erection is impaired because injury disrupts S2-S4 reflex arc, while psychogenic erections are also affected but specifically the tactile failure indicates reflex dysfunction.
  • Pharmacological Treatments:
    • PDE5 inhibitors (e.g., sildenafil, tadalafil) may be effective for reflexogenic erections
    • Their success relies on sacral reflex integrity.

Mechanism of Erection

Overview

  • Erection is a neurovascular event; increased blood to the penis and reduced venous outflow.

Phases of Erection

  1. Flaccid State:

    • Penile arterioles are constricted; minimal blood flow within the corpora cavernosa and corpus spongiosum.

  2. Initiation of Erection:

    • Triggered by:
    • Psychogenic stimulation (visual/auditory stimuli).
    • Reflexogenic stimulation (tactile).
    • Neural signals arise from higher brain centers or sacral reflex path (S2-S4).

Neurovascular Response

  • Parasympathetic Nerve Activation:
    • Pelvic splanchnic nerves (S2-S4).
  • Nitric Oxide Role:
    • Release of NO stimulates guanylyl cyclase, increases cGMP levels, causing smooth muscle relaxation.

Engorgement and Rigidity

  • Blood Flow Changes:
    • Blood fills the sinusoids in corpora cavernosa, culminating in expansion.
    • Tunica albuginea compresses venous outflow to maintain erection.

Termination of Erection

  • Resumption of vasoconstriction occurs through degradation of cGMP by phosphodiesterase-5 (PDE5).

Mechanism of Ejaculation

Overview

  • Ejaculation is a sympathetically mediated reflex with two phases: emission and expulsion.
  • Coordination between autonomic nervous system and somatic motor pathways.

Phases of Ejaculation

  1. Emission Phase:

    • Movement of sperm into posterior urethra.
    • Controlled by sympathetic nervous system (T12-L2):
    • Contraction of vas deferens, seminal vesicles, prostate gland.
    • Closure of internal urethral sphincter to prevent retrograde ejaculation.

  2. Expulsion Phase:

    • Forceful outward ejection of semen from the urethra.
    • Mediated by somatic motor neurons via pudendal nerve; coordinates rhythmic muscle contractions from bulbospongiosus and ischiocavernosus muscles.

Refractory Period

  • Following ejaculation, the penis experiences a refractory period where both erection and ejaculation are inhibited due to decreased parasympathetic activity and increased sympathetic tone.

Clinical Relevance

Erectile Dysfunction (ED)

  • Definition: Inability to achieve or maintain an erection suitable for sexual activity.
  • Possible Causes:
    • Vascular (atherosclerosis, hypertension).
    • Neurological (spinal cord injury, diabetic neuropathy).
    • Psychological (anxiety, depression).
    • Pharmacological (beta-blockers, antidepressants).

Premature Ejaculation (PE)

  • Characterization: Ejaculation with minimal stimulation, often before desired.
  • Management: Behavioral strategies and pharmacological treatments (e.g., SSRIs) to delay ejaculation.

Summary of Answers to Clinical Cases

Case 1:

  1. Mechanism impaired: Relaxation of smooth muscle in arterial supply.
  2. Beta-blocker role: Reduces blood flow and nitric oxide release inhibition.
  3. Recommended treatment: PDE5 inhibitors (e.g., sildenafil) for enhanced relaxation and increased blood flow.

Case 2:

  1. Affected phase: Expulsion phase.
  2. Neural pathways: Pudendal nerve controls rhythmic contractions.
  3. Management: Behavioral therapy and SSRIs to delay ejaculation.

Case 3:

  1. Impairment: Reflexogenic erection due to disrupted reflex arc.
  2. Critical spinal level: S2-S4 for reflexogenic pathway.
  3. Treatment response: Likely to respond to PDE5 inhibitors or intracavernosal therapy bypassing neural pathways.